VTVT vTv Therapeutics

vTv Therapeutics to Participate in the H.C. Wainwright “HCW@Home” Series

vTv Therapeutics to Participate in the H.C. Wainwright “HCW@Home” Series

HIGH POINT, N.C., June 11, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that management will participate in the H.C. Wainwright “HCW@Home” Series, being held virtually on Thursday, June 12, 2025.

Conference details are as follows:

H.C. Wainwright “HCW@Home with vTv Therapeutics”

Format: Fireside Chat

Moderator: Emily Bodnar, Director, H.C. Wainwright

vTv Therapeutics Speakers:

  • Paul Sekhri, Chairman of the Board, President & Chief Executive Officer
  • Thomas Strack, MD, Chief Medical Officer
  • Carmen Valcarce, Ph.D., Executive Vice President, Chief Scientific Officer
  • Michael Tung, MD, MBA, Chief Financial Officer

Date: Thursday, June 12, 2025

Time: 10:00 AM ET

Webcast Link: Register

The webcast of the event will be accessible from News & Events page of the vTv website.

About vTv Therapeutics

vTv Therapeutics Inc. is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. vTv's clinical pipeline is led by cadisegliatin, currently in a Phase 3 trial, a potential first-in-class oral glucokinase activator being investigated for the treatment of type 1 diabetes. vTv and its development partners are investigating multiple molecules into different indications for chronic diseases. Learn more at  or follow the company on  or .

Investor Contact

John Fraunces

LifeSci Advisors, LLC

917-355-2395

Media Contact

Caren Begun

TellMed Strategies

201-396-8551



EN
11/06/2025

Underlying

VTVTvTv Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on vTv Therapeutics

 PRESS RELEASE
Free
VTVT vTv Therapeutic...

vTv Therapeutics to Participate in the H.C. Wainwright “HCW@Home” Seri...

vTv Therapeutics to Participate in the H.C. Wainwright “HCW@Home” Series HIGH POINT, N.C., June 11, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that management will participate in the H.C. Wainwright “HCW@Home” Series, being held virtually on Thursday, June 12, 2025. Conference details are as follows: H.C. Wainwright “HCW@Home with vTv Therape...

June 11, 2025 1 EN
 PRESS RELEASE
Free
VTVT vTv Therapeutic...

vTv Therapeutics Appoints Michael Tung, M.D., MBA, to Chief Financial ...

vTv Therapeutics Appoints Michael Tung, M.D., MBA, to Chief Financial Officer as Company Reinitiates Phase 3 Trial of Oral T1D Adjunctive Therapy to Insulin HIGH POINT, N.C., May 19, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company, today announced the appointment of Michael Tung, M.D., MBA as Executive Vice President and Chief Financial Officer, effective immediately. Dr. Tung joins the Company with 20 years of diversified finance, corporate strategy, investor relations, and business development experience in the biopharmaceutical indu...

May 19, 2025 1 EN
 PRESS RELEASE
Free
VTVT vTv Therapeutic...

vTv Therapeutics Announces 2025 First Quarter Financial Results and Pr...

vTv Therapeutics Announces 2025 First Quarter Financial Results and Provides Corporate Update Ongoing screening in CATT1 Phase 3 trial evaluating cadisegliatin in patients with type 1 diabetes (T1D) Topline Phase 3 data for cadisegliatin expected in 2H 2026 HIGH POINT, N.C., May 15, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today reported financial results ...

May 15, 2025 1 EN
 PRESS RELEASE
Free
VTVT vTv Therapeutic...

vTv Therapeutics Announces Reinitiation of Screening in CATT1 Phase 3 ...

vTv Therapeutics Announces Reinitiation of Screening in CATT1 Phase 3 Trial Evaluating Potential First-in-Class Liver-Selective Glucokinase Activator Cadisegliatin for Type 1 Diabetes Topline CATT1 Phase 3 data is expected in 2H 2026 Protocol amendment shortens trial duration from 12 to 6 months, expediting time to topline data HIGH POINT, N.C., May 15, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company with an innovative clinical portfolio of small molecules and lead program in diabetes, today announced that screening has been reinitia...

May 15, 2025 1 EN
 PRESS RELEASE
Free
VTVT vTv Therapeutic...

vTv Therapeutics Announces 2024 Fourth Quarter and Full Year Financial...

vTv Therapeutics Announces 2024 Fourth Quarter and Full Year Financial Results and Provides Corporate Update Clinical hold lifted for late stage cadisegliatin program for diabetes CATT1 Phase 3 trial in patients with type 1 diabetes (T1D) expected to resume Q2 2025 Strengthens commercial leadership with appointment of Martin Lafontaine as Chief Commercial Officer HIGH POINT, N.C., March 20, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin, a potential first-in-class oral adjunctive ther...

March 20, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch